Shobhit Seth

Shobhit Seth is a freelance financial writer, derivatives trader and consultant specializing in derivatives pricing and quantitative research. His career spans over 14 years as a Product Manager (Derivatives, Financial Data & Risk Management) at leading financial services companies across the UK, Europe, US and India. He has written extensively on topics pertaining to Derivatives Pricing, Derivatives Combinations & Structures, and Derivatives Trading Strategies. A lot of his work is available at, a site on Derivatives Trading which Shobhit owns and maintains. Shobhit also has expertise in index based products and ETFs, and he conducts training sessions on derivatives and related financial topics.

Shobhit has a Master’s degree in Financial Management (Specialization in Derivatives & Quantitative Research) from the Netherlands and a Bachelor of Technology degree (Electronics & Communications Engineering) from India.

  • Showing 1-15 of 485 items
  • 1
  • 2
  • 3
  • ...
  • 33
  • >>
  1. Company Insights

    Alexion Gets U.K. Approval for High-Cost Drug (ALXN)

    Though user base is small for this rare disease, the high annual cost of up to $2 million offers attractive commercials for Alexion.
  2. Company Insights

    Sarpeta Approval Challenged by FDA (SRPT)

    Will Sarepta’s approval be revoked following the FDA commissioner’s call for retraction of the company's 2013 study?
  3. Laws & Regulations

    Sarpeta Raises Offering After FDA Approval (SRPT)

    Sarepta has increased the amount of capital to be raised to $300 million in a public offering
  4. Company Insights

    Global Licensing Deal Spikes Geron Stock (GERN, JNJ)

    Building upon an existing 2014 agreement, Geron and Jenssen have struck a renewed global partnership on multiple products.
  5. Company Insights

    BARDA Increases Cytori Therapeutics’ Contract Option (CYTX)

    The renewed contract option indicates on-track progress of Cytori Cell Therapy, along with increased valuations.
  6. Laws & Regulations

    Annex Shows Positive Parkinson's Drug Data (AVXL)

    Anavex Life Sciences’ ANAVEX 2-73 drug shows efficacy to support potential disease modification in Parkinson's disease
  7. Company Insights

    AVEO Collaborates With Bristol-Myers Squibb for RCC Drug ...

    AVEO initiates clinical trial with a unique combination of drugs for treating advanced stage RCC.
  8. Company Insights

    Will Gilead Make a Good Fit for Allergan? (GILD)

    Allergan made two recent acquisitions in the NASH diseases space, and Gilead’s strong NASH drug portfolio can fit well with these.
  9. Company Insights

    Gilead Ends Bowel Disease Treatment Trials (GILD)

    Gilead is halting the GS-5745 trials amid insufficient evidence of efficiency for treating ulcerative colitis IBD.
  10. Company Insights

    Biogen Bets on Nusinersen (BIIB, IONS)

    Biogen’s SMA drug nusinersen can emerge as a big winner in the mid- to long-term.
  11. Company Insights

    Ariad Receives Interest as a Buyout Candidate

    Following failed buyout talks with Baxalta last year, Ariad’s stock is spiking amid rumors of a takeover.
  12. Stocks

    Sarepta Announces Offering of Common Stock (SRPT)

    Sarepta Therapeutics announces a $225 million capital-raising public offering.
  13. Company Insights

    Eleven Biotherapeutics Acquires Viventia Bio

    This acquisition creates the first listed company working on Targeted Protein Therapeutics Oncology.
  14. Company Insights

    Sarepta Wins Favorable USPTO Decisions (SRPT)

    Sarepta records another success with a positive decision from the U.S. Patent and Trademark Office.
  15. Laws & Regulations

    Mast Therapeutics Crash Led By Poor Results (MSTX)

    The company's shares have suffered in the wake of failed drug studies that forced it to cancel clinical development plans
  • Showing 1-15 of 485 items
  • 1
  • 2
  • 3
  • ...
  • 33
  • >>